Latest Headlines

  1. CRDMO Aragen Completes Facility And Equipment Qualification; First GMP batches In Late July 2025 6/20/2025

    Aragen, a leading contract research, development and manufacturing organization (CRDMO), announced that it will commence GMP manufacturing at its biologics manufacturing facility in Bangalore, India from late July 2025. Aragen has successfully completed the facility and equipment qualification and demonstrated the productivity of its intensified fed batch cell culture manufacturing platform to deliver titers >25 g/L.

  2. Leading European Biologics CDMO Mabion, Releases First Batch Of Novalgen's Next-Generation T-Cell Engager, NVG-222 For First In-Human Clinical Trials 6/17/2025

    In a significant move to accelerate the global fight against blood cancers and hard-totreat solid tumours, renowned end-to-end biologics CDMO Mabion have entered into a strategic development and manufacturing partnership with London based NovalGen an existing client with whom cooperation under CDMO orders was first disclosed in current report No. 13/2024 dated August 16, 2024.

  3. Mabion Launches €500,000 Services Contest To Support Next-Gen Oncology Breakthroughs 6/17/2025

    Mabion, a leading biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025, aimed at accelerating the development of, recombinant protein-based cancer therapies.

  4. Ecolab Life Sciences Launches New Bioprocessing Purification Resin To Drive Manufacturing Productivity 6/16/2025

    Ecolab Life Sciences today announced it has launched an innovative new resin to help achieve cost savings and optimize operations throughout the antibody manufacturing process.

  5. Nanoform Starts Pivotal Human Bioequivalence Studies Of Nanoenzalutamide 6/12/2025

    Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had started pivotal relative bioequivalence studies of Nanoenzalutamide, the nanocrystalline-enabled enzalutamide tablet formulation, a potential alternative to the amorphous solid dispersion (ASD) used in XTANDI® (enzalutamide) [1], the number one prescribed androgen receptor inhibitor [2] approved to treat prostate cancer.

  6. Parker To help Biopharmaceutical Manufacturers Transform Tangential Flow Filtration 6/12/2025

    Optimizing, streamlining and scaling tangential flow filtration processing in the biopharmaceutical industry will be the focus of a Parker webinar this month.

  7. Simtra BioPharma Solutions And MilliporeSigma Announce Strategic Alliance For Antibody Drug Conjugates Drug Substance And Drug Product Manufacturing Services 6/12/2025
  8. Bora Adds Automated Fill/Finish Line In Baltimore 5/29/2025

    Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, today announced that due to continued growth in demand for its drug product services, it plans to add further sterile fill/finish capacity at its facility in Baltimore, Maryland.

  9. CDMO Bora Biologics Announces Plans To Expand San Diego Manufacturing Facility 5/22/2025

    Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a premier biologics CDMO.

  10. Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy 5/15/2025

    Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC).